Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

177 - lutetium PNT 2001 - POINT Biopharma

X
Drug Profile

177 - lutetium PNT 2001 - POINT Biopharma

Alternative Names: 177Lu-PNT2001; PNT-2001 Lu-177 isotope; PNT-2001 lutetium 177 isotope

Latest Information Update: 01 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Scintomics
  • Developer POINT Biopharma
  • Class Amides; Antineoplastics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Prostate cancer

Most Recent Events

  • 27 Dec 2023 POINT Biopharma has been acquired by Eli Lilly and Company
  • 04 Jan 2022 177 - lutetium PNT 2001 is available for licensing as of 04 Jan 2022. https://www.pointbiopharma.com/contact-us
  • 18 May 2021 POINT Biopharma has patents pending for PNT 2001 in the US, Europe, Australia and Chile
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top